Novavax is a late-stage clinical biotechnology company with a recombinant subunit innovative vaccine platform and an adjuvant platform to develop prophylactic vaccines against infectious diseases.?


  • This 29-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect Novavax. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

    Reasons To Buy
  • An overview of how Novavax Inc. will be affected by the COVID-19 pandemic.